QDEL · QuidelOrtho Corporation
$16.05
-0.95% last session
End-of-day data · updated 2026-07-28
Market cap
$1B
Enterprise value
$4B
Trailing P/E
—
Forward P/E
6.9
Dividend yield
—
Beta
0.69
Avg volume
2M
Employees
6K
2D change
4.86%
5D change
1.51%
10D change
-3.16%
30D change
22.04%
60D change
29.26%
MTD change
-7.43%
YTD change
-41.07%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — QDEL
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-08
Latest call per bank · past 12 months
Citigroup
Neutral$18.00
+12.1% vs priceJP Morgan
Underweight$12.00
-25.2% vs priceJefferies
Hold$12.50
-22.1% vs priceUBS
Neutral$17.00
+5.9% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-08 | Citigroup | Maintains | Neutral | $13.00 → $18.00 |
| 2026-07-01 | JP Morgan | Maintains | Underweight | $11.00 → $12.00 |
| 2026-05-07 | Jefferies | Downgrade | Buy → Hold | $35.00 → $12.50 |
| 2026-05-06 | Citigroup | Maintains | Neutral | $30.00 → $13.00 |
| 2026-04-10 | UBS | Maintains | Neutral | $30.00 → $17.00 |
| 2026-02-12 | Citigroup | Maintains | Neutral | $23.00 → $30.00 |
| 2026-01-21 | UBS | Maintains | Neutral | $31.00 → $35.00 |
| 2025-11-07 | JP Morgan | Maintains | Underweight | $26.00 → $22.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 53 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 12.8% above the 50-day MA ($14.78).
- Price vs 200-day MA: Trading 20.9% below the 200-day MA ($21.07).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.27) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($9.96) and high ($35.38).
QDEL Price Chart
Loading chart for QDEL…
Fundamentals
About QuidelOrtho Corporation
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.
More in Medical Devices
ABT
Abbott Laboratories
$182B -15.0% YTD
SYK
Stryker Corporation
$129B -3.7% YTD
MDT
Medtronic plc.
$108B -10.8% YTD
BSX
Boston Scientific Corporation
$68B -52.3% YTD
EW
Edwards Lifesciences Corporatio
$48B -2.6% YTD
GEHC
GE HealthCare Technologies Inc.
$28B -25.4% YTD
DXCM
DexCom, Inc.
$28B 10.5% YTD
PHG
Koninklijke Philips N.V. NY Reg
$24B -4.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.